In an updated guideline, two medical groups—the American Heart Association and the American College of Cardiology—have endorsed AstraZeneca blood thinner Brilinta over Bristol-Myers Squibb’s now off-patent antiplatelet drug Plavix. The guidance to physicians involves management of non-ST-elevation acute coronary syndromes, or acute chest pain without electrocardiogram changes, Reuters reported Monday. AZ stated that it was the first time that cardiology organizations had recommended one drug over another for acute coronary syndrome.
Cardiology groups endorse AZ’s Brilinta over Plavix
Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.
